跳至主要内容
临床试验/CTRI/2019/05/019139
CTRI/2019/05/019139已完成不适用

The Efficacy and Tolerability of Itraconazole oral solution in Paediatric Dermatophytosis

Dr Ramesh Bhat M1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年5月15日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Safety and Efficacy of Oral Itraconasole solution in Paediatric age group

研究概览

简要总结

Purpose of Trial

Presently dermatophytosis in India is resistant to treat and itraconazole is the widely used drug for the management considering the low response rate for previously used drugs like terbinafine, fluconazole and griseofulvin. Even though dermatophytosis in children is rare compared to adults, in the present epidemic it is seen in children also and the management of these recurrent and resistant dermatophytosis is a therapeutic challenge.

Even though itraconazole in capsule form is widely used, it is difficult to administer it in children considering the size of the capsule. In view of the recent availability of itraconazole oral solution, this can be effectively administered with ease in children. However, there are only a few studies in the literature for the treatment of dermatophytosis with oral Itraconazole solution, hence this study is conducted.

Itraconazole oral solution is efficacious and tolerable in Paediatric Dermatophytosis.

研究设计

研究类型
Interventional
分配方式
Other
盲法
Not Applicable

入排标准

年龄范围
1.00 Year(s) 至 12.00 Year(s)(—)
性别
All

入选标准

  • Patients age group of 1to12 years with clinical diagnosis of cutaneous dermatophytosis in glabrous skin (Tinea faciei, Tinea corporis and Tinea Cruris).
  • Both boys and girls will be included in the study.
  • Patients /parents/guardians who are consenting to participate in the study.
  • Patients with recurrent and extensive (10% body surface area) Tinea infection will be taken for the study.

排除标准

  • •Patients with other pre-existing skin disorders.
  • •Patients/parents/guardians who are not willing to participate in the study.

结局指标

主要结局

Safety and Efficacy of Oral Itraconasole solution in Paediatric age group

时间窗: Two weeks and Four weeks

次要结局

  • Tolerability and side effects of oral itraconazole solution(2 weeks and 4 weeks)

研究者

发起方
Dr Ramesh Bhat M
申办方类型
Other [investigator initiated project]

研究点 (1)

Loading locations...

相似试验